Gilead Sciences (GILD) Revenue (2009 - 2026)
Gilead Sciences' (GILD) quarterly Revenue came in at $7.0 billion in Q1 2026, up 4.39% YoY from $6.7 billion in Q1 2025, and down 12.18% on a QoQ basis from $7.9 billion in Q4 2025.
Gilead Sciences (GILD) Revenue (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Revenue data on file, last reported at $7.0 billion in Q1 2026.
- Quarterly Revenue rose 4.39% year-over-year to $7.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.7 billion (up 3.48% YoY) and the FY2025 annual result came in at $29.4 billion, up 2.4% from the prior year.
- Revenue slipped to $7.0 billion in Q1 2026, from $7.9 billion in the prior quarter.
- In the past five years, Revenue ranged from a high of $7.9 billion in Q4 2025 to a low of $6.3 billion in Q2 2022.
- A 5-year average of $7.0 billion and a median of $7.0 billion in 2022 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue decreased 5.11% — and 2024, when it advanced 7.01%.
- Tracing GILD's Revenue over 5 years: stood at $7.4 billion in 2022, then fell by 3.72% to $7.1 billion in 2023, then grew by 6.4% to $7.6 billion in 2024, then climbed by 4.7% to $7.9 billion in 2025, then slipped by 12.18% to $7.0 billion in 2026.
- The last three Revenue figures came in at $7.0 billion (Q1 2026), $7.9 billion (Q4 2025), and $7.8 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 25.31 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 16.99 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 16.61 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 14.41 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 15.38 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 10.05 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 7.80 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 15.03 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 11.28 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 13.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.80 Bn |
| Mar 31, 2026 | 6.96 Bn |
| Dec 31, 2025 | 7.93 Bn |
| Sep 30, 2025 | 7.77 Bn |
| Jun 30, 2025 | 7.08 Bn |
| Mar 31, 2025 | 6.67 Bn |
| Dec 31, 2024 | 7.57 Bn |
| Sep 30, 2024 | 7.55 Bn |
| Jun 30, 2024 | 6.95 Bn |
| Mar 31, 2024 | 6.69 Bn |
| Dec 31, 2023 | 7.11 Bn |
| Sep 30, 2023 | 7.05 Bn |
| Jun 30, 2023 | 6.60 Bn |
| Mar 31, 2023 | 6.35 Bn |
| Dec 31, 2022 | 7.39 Bn |
| Sep 30, 2022 | 7.04 Bn |
| Jun 30, 2022 | 6.26 Bn |
| Mar 31, 2022 | 6.59 Bn |
| Dec 31, 2021 | 7.24 Bn |
| Sep 30, 2021 | 7.42 Bn |